Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

BACKGROUND: The first phase of the Psoriasis Longitudinal Assessment and Registry (PSOLAR) provided safety, demographic, and other outcomes data from >12,000 patients (>75,000 patient-years) eligible to receive biologics for psoriasis. In 2018, PSOLAR enrollment criteria were updated to specifically include patients receiving either guselkumab or an interleukin-17 inhibitor (IL-17i). METHODS: Baseline characteristics are described for patients included in PSOLAR after adoption of Protocol Amendment 6 (March 26, 2018), which updated enrollment criteria to include patients exposed to guselkumab or an IL-17i. RESULTS: As of July 12, 2025, 3501 patients (guselkumab, n = 2213; IL-17i, n = 1288) were enrolled at sites in 17 countries. Baseline characteristics were generally balanced between the guselkumab and IL-17i cohorts. The majority of patients were male (59.9%), white (74.3%), and overweight/obese (78.5%; mean [SD] BMI = 30.2 [7.2] kg/m2). Mean (SD) age was 50.3 (13.9) years. On average, patients had longstanding psoriasis at baseline (mean [SD] duration of psoriasis = 19.0 [13.7] years; mean [SD] body surface area = 8.6% [12.7]). Most patients reported current or prior history of alcohol use (77.3%) and smoking (54.1%). Prior to enrollment, most patients (76.9%) reported exposure to ≥1 biologic. Self-reported psoriatic arthritis was less common in the guselkumab vs the IL-17i group (25.0% vs 38.1%). CONCLUSION: Patients with psoriasis treated with guselkumab or an IL-17i in this real-world cohort had similar baseline characteristics, although psoriatic arthritis was more common in the IL-17i group. Findings from PSOLAR may help clinicians better understand characteristics of patients who may be prescribed guselkumab or an IL-17i for psoriasis in a real-world setting. CLINICALTRIALSGOV IDENTIFIER: NCT00508547.